05:38 PM EDT, 08/18/2025 (MT Newswires) -- iBio (IBIO) said late Monday it launched an underwritten public offering of pre-funded warrants to purchase common shares, along with accompanying series G and series H warrants, each representing rights to buy fractions of common shares or pre-funded warrants.

The company said it plans to use the net proceeds to advance its preclinical cardiometabolic programs, including IBIO ( IBIO )-610 and IBIO ( IBIO )-600, progress other pipeline assets, and for general corporate purposes.